The veterinary vaccine manufacturers industry in Europe is a vital sector focusing on developing vaccines to combat diseases affecting animals. Companies in this field range from small biotech startups to large pharmaceutical firms, providing innovative products tailored for livestock, pets, and exotic animals. The industry is on a growth trajectory, bolstered by increased animal health awareness and stringent food safety regulations. Not only do these vaccines aim to improve animal welfare and health, but they also play a critical role in safeguarding public health by controlling zoonotic diseases. Moreover, advancements in vaccine technology, such as mRNA vaccines, hint at a promising future.


The investors profiled in this article include venture capital firms, private equity groups, and corporate investors, predominantly located in major European cities. They range in size from small teams to large organizations, with years of establishment spanning from the late 20th century to recent times. In 2024, these investors executed various deals, reflecting their keen interest in the veterinary vaccine sector. Noteworthy examples include Novo Holdings in Denmark and Seventure Partners in France, among others.


Top 19 Veterinary Vaccine Manufacturers Investors in Europe


1. CVS Group plc

  • Website: cvsukltd.co.uk
  • Type: Corporate
  • Headquarters: Diss, England, United Kingdom (UK)
  • Founded year: 1999
  • Headcount: 5001-10000
  • Number of deals in 2024: 1
  • LinkedIn:

CVS Group plc is a corporate investor based in Diss, England, founded in 1999. The company operates as a veterinary services provider, offering a wide range of services including veterinary care, pet insurance, and health programs for small animals, equine, and farm animals. CVS Group plc has been actively acquiring veterinary practices to expand its network across the UK. Notable acquisitions include O'Reilly & Fee Veterinary Surgery in December 2016, Putlands Veterinary Surgery in June 2016, and Archway Veterinary Practice in March 2013. These transactions reflect CVS's commitment to enhancing veterinary care and services, which are integral to the veterinary vaccine manufacturers industry, as they rely on veterinary practices for the administration and promotion of vaccines.


2. Bpifrance French Tech Accélération


Bpifrance French Tech Accélération is a venture capital firm based in Paris, Île-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally by providing a range of services, including direct funding, export credit insurance, and private equity investments. The firm aims to foster entrepreneurship and innovation through coaching and partnerships, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several significant transactions within the veterinary vaccine sector, including investments in Vaxinano, which raised approximately $6.5 million in a venture round, and Vetbiolix, which raised over $4.2 million in a venture round and $2.8 million in a seed round. These investments highlight Bpifrance's active role in supporting companies that are developing veterinary vaccines, aligning with their mission to promote innovation in various industries.


3. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. The firm provides capital and strategic support to enhance healthcare solutions. Notably, Novo Holdings has been involved in several transactions relevant to the veterinary vaccine sector. For instance, they participated in a Series B financing round for Invetx, which raised US$60.5 million to advance its monoclonal antibody pipeline targeting diseases in dogs and cats. Additionally, they have invested in Minervax, which raised significant funding for its projects, potentially related to vaccine development. These transactions highlight Novo Holdings' commitment to supporting innovations in veterinary health, making them a relevant investor in the veterinary vaccine manufacturers industry.


4. Scottish Enterprise


Scottish Enterprise is a public entity established in 1991, based in Glasgow, Scotland, focused on economic development and innovation support for businesses in Scotland. It provides funding, business development advice, and assistance for exports. In recent years, Scottish Enterprise has been involved in several significant transactions relevant to the veterinary sector. Notably, it awarded research and development funding of up to £20 million to Valneva, which includes support for vaccine manufacturing processes. Additionally, Scottish Enterprise participated in funding rounds for Biotangents, a Scottish biotechnology company that is developing rapid disease detection technology for animal health. These transactions highlight Scottish Enterprise's role in fostering innovation and growth within the veterinary vaccine and diagnostics space, making it a relevant investor in this industry.


5. Seventure Partners

  • Website: seventure.fr
  • Type: Venture Capital
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1997
  • Headcount: 11-50
  • Number of deals in 2024: 21
  • LinkedIn: seventure-partners

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in managing funds for innovative companies in the digital technology and life sciences sectors. They focus on supporting startups and growth-stage companies through strategic funding. Notably, Seventure has invested in several companies within the veterinary sector, including ViroVet, which raised over 6 million euros to develop its veterinary product portfolio, and Animab, which secured 3.4 million euros for developing monoclonal antibodies aimed at improving livestock health. Additionally, they participated in funding for Proteon Pharmaceuticals, which aims to reduce antibiotic reliance in animal agriculture. These transactions highlight Seventure's commitment to advancing veterinary health solutions.


6. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent investment firm founded in 1994, specializing in private equity, infrastructure, real estate, growth equity, and venture capital. Based in Stockholm, Sweden, EQT serves institutional investors by managing diverse investment portfolios across various sectors and geographies. In the veterinary sector, EQT has made significant investments, including a substantial stake in IVC Evidensia, Europe's largest veterinary care provider, and acquisitions of Evidensia Djursjukvård, Independent Vetcare, and VetPartners. These transactions highlight EQT's commitment to enhancing veterinary services, which are integral to the veterinary vaccine market. Their involvement in these companies positions them as a key player in the veterinary industry, making them a relevant investor in the context of veterinary vaccines.


7. IK Partners

  • Website: ikpartners.com
  • Type: Private Equity
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1989
  • Headcount: 201-500
  • Number of deals in 2024: 14
  • LinkedIn: ik-investment-partners

IK Partners is a private equity firm based in London, England, specializing in mid-market investments across Europe. Founded in 1989, the firm focuses on providing capital and strategic support to businesses in various sectors, including Business Services, Healthcare, Consumer, and Industrials. Notably, IK Partners has made significant investments in the veterinary sector, including the acquisition of CEVA Santé Animale, a leading veterinary pharmaceutical company, in 2003 and again in 2004. They have also acquired CID LINES, Innovad, and Kersia, all of which are involved in veterinary health and related products. These transactions highlight IK Partners' commitment to enhancing growth and creating long-term value in the veterinary vaccine and healthcare market.


8. 3i Group plc

  • Website: 3i.com
  • Type: Private Equity
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1945
  • Headcount: 201-500
  • Number of deals in 2024: 3
  • LinkedIn: 3i-group-plc

3i Group plc is a London-based private equity firm founded in 1945, specializing in private equity and infrastructure investments. The firm focuses on providing capital and expertise to mid-market companies, helping them grow sustainably. With a strong international presence and a diverse portfolio, 3i Group aims to create value for its stakeholders through strategic investments. Notably, 3i Group has made significant investments in the veterinary sector, including the acquisition of Phibro Animal Health in 2008, a company that produces a range of animal health products, including vaccines. Additionally, their investment in Vetoquinol, a company known for its veterinary pharmaceuticals, further emphasizes their involvement in the veterinary market. These transactions highlight 3i Group's commitment to supporting companies that contribute to animal health and welfare.


9. Merieux Equity Partners


Mérieux Equity Partners is a private equity investment firm based in Lyon, France, founded in 2009. The firm specializes in healthcare investments, focusing on venture capital and buyout strategies. They aim to support the growth of healthcare companies by providing capital and strategic guidance, primarily targeting businesses in medical devices, pharmaceuticals, and life sciences. Notably, Mérieux Equity Partners has been involved in several significant transactions in the veterinary vaccine sector, including multiple investments in Ceva Santé Animale, a leading veterinary pharmaceutical company known for its vaccine products. They have participated in funding rounds for Ceva Santé Animale in 2014, 2020, and 2025, demonstrating a sustained commitment to the veterinary vaccine market. Additionally, their investment in AstriVax, which is developing a thermostable yellow fever vaccine and other vaccine candidates, showcases their broader interest in vaccine development, which may extend to veterinary applications. Their approach emphasizes responsible investing and collaboration with management teams to foster innovation and development in the healthcare sector.


10. Portugal Ventures


Portugal Ventures is a venture capital firm based in Porto, Portugal, founded in 2012. The firm specializes in investing in startups with global ambitions, primarily located in Portugal, and provides both capital and strategic support to help these startups grow and scale their operations. Portugal Ventures focuses on innovative projects across various sectors, including technology and health. Among their notable transactions, they have invested in Immunethep, a biotech company that is developing technology for clinical trials, which is relevant to the veterinary vaccine sector. Additionally, they have supported Barkyn, a company that provides services for pet care, indicating their interest in the broader pet health market. Their involvement in these sectors positions them as a potential investor in veterinary vaccine manufacturers.


11. Ardian

  • Website: ardian.com
  • Type: Private Equity
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1996
  • Headcount: 1001-5000
  • Number of deals in 2024: 21
  • LinkedIn: ardian

Ardian is a prominent investment management firm founded in 1996, specializing in private equity, real assets, and credit solutions. With a global presence and a focus on sustainable finance, Ardian aims to create lasting value for its clients, which include institutional investors, family offices, and pension funds. Notably, Ardian has made significant investments in the veterinary sector, including a debt financing round for Ceva Santé Animale, which raised over $129 million, indicating its engagement in the animal health market. Furthermore, Ardian's recent acquisition of a minority stake in Mon Véto, a leading independent group of veterinary clinics in France, highlights its strategy to support growth in the veterinary industry. These transactions demonstrate Ardian's active role in the veterinary sector, particularly in areas related to animal health and veterinary services.


12. SoftBank Investment Advisers


SoftBank Investment Advisers, also known as the SoftBank Vision Fund, is a venture capital firm based in London, UK, founded in 2017. The firm specializes in investing in technology-focused companies, particularly those innovating in artificial intelligence and health tech. Their diverse portfolio includes significant investments in various sectors, including veterinary health. Notably, they led a $75M Series B funding round for Embark Veterinary, a company dedicated to enhancing the health and lifespan of dogs, which is directly relevant to veterinary vaccines. Additionally, they participated in funding rounds for Abogen Biosciences, a Chinese mRNA vaccine developer, which, while primarily focused on human health, showcases their commitment to vaccine development. These transactions highlight SoftBank's interest in health-related innovations, including those that could impact veterinary medicine.


13. Wellington Partners


Wellington Partners is a venture capital firm based in Munich, Bavaria, Germany, founded in 1998. The firm specializes in life sciences, focusing on early- and growth-stage companies. They provide capital and strategic support to entrepreneurs in various sectors, including therapeutics and medical devices. Notably, Wellington Partners has been involved in significant transactions such as their investment in MinervaX, a Danish biotech company that raised substantial funding for the development of a Group B Streptococcus (GBS) vaccine candidate. This vaccine is particularly relevant as it aims to prevent life-threatening infections in newborns, showcasing Wellington's commitment to advancing vaccine technologies. Their recent investments, including a Series A funding round for SciRhom, further illustrate their active role in supporting innovative life sciences ventures.


14. Boehringer Ingelheim Venture Fund

  • Website: boehringer-ingelheim-venture.com
  • Type: Venture Capital
  • Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
  • Founded year: 2010
  • Headcount: 11-50
  • Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund focuses on investing in pioneering science and biotechnology innovations, particularly in the healthcare sector. They provide both capital and expertise to startups, helping them develop and commercialize their products. Notably, the fund led a USD 14 million seed financing round for Delonix Bioworks, which is building synthetic biology vaccine platforms, indicating a direct interest in vaccine development. Additionally, their involvement in the funding of Ruipeng Pet Healthcare highlights their commitment to the veterinary sector, as this company aims to improve pet healthcare systems. Overall, their investment strategy encompasses a range of healthcare innovations, including those relevant to veterinary vaccines.


15. Crédit Mutuel Equity


Crédit Mutuel Equity is a private equity investment firm based in Paris, Île-De-France, France, founded in 1988. The firm specializes in providing capital and strategic support to businesses, helping them grow and transform by integrating economic and ESG considerations into their strategies. Their clientele includes business leaders from various sectors seeking to enhance their operations and navigate market challenges. Notably, Crédit Mutuel Equity has been involved in several transactions relevant to the veterinary vaccine manufacturers context, including a significant investment in Groupe Grimaud La Corbière, which raised over $70 million in a private equity round in 2011. This company is known for its work in animal health and breeding, which includes veterinary vaccines. Other transactions, such as their acquisition of Technoflex and investments in companies like Lim Group and Gen.Orph, showcase their diverse investment approach, although these are less directly related to veterinary vaccines.


16. Cvc

  • Website: cvc.com
  • Type: Private Equity
  • Headquarters: Luxembourg
  • Founded year: 2005
  • Headcount: 1001-5000
  • Number of deals in 2024: 16
  • LinkedIn: cvc-capital-partners

CVC Capital Partners is a prominent investment firm founded in 2005, specializing in private equity, credit, secondaries, and infrastructure. With approximately €193 billion in assets under management for over 1000 clients, including pension funds and institutional investors, CVC focuses on delivering sustainable value and growth through strategic investments. Notably, CVC has made significant investments in the veterinary sector, including the acquisition of a majority stake in Medivet for over £1 billion, which operates more than 350 veterinary branches in the UK. This acquisition highlights CVC's commitment to expanding its footprint in the veterinary industry. Additionally, CVC has a history of investing in related sectors, such as their acquisition of Petco, a major pet retailer, and Provimi, a company involved in animal nutrition, further showcasing their interest in the broader animal health and welfare market.


17. Eurazeo

  • Website: eurazeo.com
  • Type: Private Equity
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1969
  • Headcount: 201-500
  • Number of deals in 2024: 40
  • LinkedIn: eurazeo

Eurazeo is a prominent investment management firm based in Paris, specializing in private equity, private debt, and real assets. Founded in 1969, the firm has established a significant presence in the investment management landscape, particularly in Europe. Eurazeo provides tailored investment strategies aimed at fostering growth and expansion across various sectors, including technology and healthcare. Notably, Eurazeo has been involved in several transactions relevant to the veterinary and life sciences sectors, such as leading a €60 million fundraise for M2I Life Sciences, which operates in the life sciences domain. They also participated in a venture round for Olmix SA, a company that focuses on natural solutions for agriculture and animal health. Furthermore, their acquisition of Ultra Premium Direct, a French pet food brand, highlights their engagement in the pet industry, which is closely linked to veterinary health. These transactions reflect Eurazeo's commitment to investing in sectors that could potentially include veterinary applications.


18. Nestlé

  • Website: nestle.com
  • Type: Corporate
  • Headquarters: Vevey, Vaud, Switzerland
  • Founded year: 1866
  • Headcount: 10001+
  • Number of deals in 2024: 2
  • LinkedIn: nestle-s-a-

Nestlé S.A. is a multinational food and beverage company based in Vevey, Vaud, Switzerland, founded in 1866. The company offers a diverse range of products, including coffee, dairy, and pet care items, and operates globally with a commitment to sustainability. In recent years, Nestlé has made significant investments in the veterinary care sector, including a notable investment in IVC Evidensia, Europe's largest veterinary care provider, which raised €3.5 billion in private funding. Additionally, Nestlé participated in the funding round for Prometheus Biosciences, a biotechnology company, and has been involved with Independent Vetcare, which raised over $4 billion in private equity. Furthermore, Nestlé's acquisition of Ralston Purina Company in 2001 and Waggin’ Train in 2010 highlights its long-standing commitment to the pet care industry, reinforcing its relevance in the veterinary market.


19. The Yield Lab

  • Website: theyieldlab.com
  • Type: Venture Capital
  • Headquarters: Killiney, Dublin, Ireland
  • Founded year: 2014
  • Headcount: 11-50
  • Number of deals in 2024: 2
  • LinkedIn: theyieldlab

The Yield Lab is a venture capital firm based in Killiney, Dublin, Ireland, founded in 2014. It specializes in agrifood technology investments, providing early-stage companies with venture capital funding, access to a global network of experts, and educational resources. The firm has been involved in several relevant transactions, including investments in Aptimmune, which raised $6 million in Series B funding and $100,000 in a convertible note, both aimed at developing veterinary vaccines. Additionally, they invested in EIO Diagnostics, which raised $620,000, potentially indicating a broader interest in veterinary diagnostics and related technologies. Their focus on supporting innovations in the agrifood sector positions them as a relevant investor in the veterinary vaccine manufacturing space.



Veterinary Vaccine Manufacturers Insights: Key Investors in Europe


InvestorHeadquarterSizeFoundedDeals 2024
CVS Group plcDiss, England, United Kingdom (UK)5001-1000019991
Bpifrance French Tech AccélérationParis, Île-De-France, France1-102015198
Novo HoldingsHellerup, Denmark51-200199945
Scottish EnterpriseGlasgow, Scotland, United Kingdom (UK)1001-5000199155
Seventure PartnersParis, Île-De-France, France11-50199721
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
IK PartnersLondon, England, United Kingdom (UK)201-500198914
3i Group plcLondon, England, United Kingdom (UK)201-50019453
Merieux Equity PartnersLyon, Auvergne-Rhône-Alpes, France11-5020093
Portugal VenturesPorto, Porto, Portugal11-5020126
ArdianParis, Île-De-France, France1001-5000199621
SoftBank Investment AdvisersLondon, England, United Kingdom (UK)201-500201714
Wellington PartnersMunich, Bavaria, Germany11-5019989
Boehringer Ingelheim Venture FundIngelheim Am Rhein, Rhineland-Palatinate, Germany11-5020105
Crédit Mutuel EquityParis, Île-De-France, France51-20019882
CvcLuxembourg1001-5000200516
EurazeoParis, Île-De-France, France201-500196940
NestléVevey, Vaud, Switzerland10001+18662
The Yield LabKilliney, Dublin, Ireland11-5020142


Want to find more investors focusing on the veterinary vaccine manufacturers industry?

If you want to find more investors that are active in the veterinary vaccine manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!